|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3431485B2
(en)
|
2010-10-01 |
2024-09-04 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
MX2014001971A
(es)
*
|
2011-08-26 |
2014-03-31 |
Arrowhead Res Corp |
Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.
|
|
EP2751270B1
(en)
|
2011-08-29 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US8796405B2
(en)
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
|
MX2014001965A
(es)
*
|
2012-04-18 |
2014-03-31 |
Arrowhead Res Corp |
Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US9868949B2
(en)
|
2013-02-28 |
2018-01-16 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat EPAS1-related diseases
|
|
HK1220368A1
(zh)
|
2013-03-13 |
2017-05-05 |
Cour Pharmaceuticals Development Company |
用於治疗炎症的免疫修饰性颗粒
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
KR102482890B1
(ko)
|
2013-05-01 |
2022-12-30 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
|
|
CN105451743B
(zh)
|
2013-08-07 |
2019-11-19 |
箭头研究公司 |
用于在活体中递送RNAi触发子至肿瘤细胞的聚偶联物
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
CN106232125B
(zh)
|
2014-05-01 |
2020-10-16 |
Ionis制药公司 |
用于调节pkk表达的组合物和方法
|
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
|
PE20170010A1
(es)
|
2014-05-01 |
2017-03-04 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
MX2017014641A
(es)
|
2015-05-29 |
2018-01-23 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
|
|
PE20180800A1
(es)
|
2015-07-10 |
2018-05-09 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
|
TW201723176A
(zh)
|
2015-09-24 |
2017-07-01 |
Ionis製藥公司 |
Kras表現之調節劑
|
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
MA52645B1
(fr)
|
2015-10-22 |
2022-06-30 |
Modernatx Inc |
Vaccins contre le virus respiratoire
|
|
MA46316A
(fr)
|
2015-10-22 |
2021-03-24 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
CA3003103A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
CN117731769A
(zh)
|
2015-10-22 |
2024-03-22 |
摩登纳特斯有限公司 |
用于水痘带状疱疹病毒(vzv)的核酸疫苗
|
|
KR20180096592A
(ko)
|
2015-10-22 |
2018-08-29 |
모더나티엑스, 인크. |
호흡기 세포융합 바이러스 백신
|
|
MX2018004918A
(es)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna del virus herpes simple.
|
|
DK4119569T3
(da)
|
2015-11-06 |
2024-08-12 |
Ionis Pharmaceuticals Inc |
Konjugerede antisense-forbindelser til anvendelse i behandling
|
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
EP4039699A1
(en)
|
2015-12-23 |
2022-08-10 |
ModernaTX, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
CN109069529B
(zh)
|
2016-03-07 |
2021-08-20 |
箭头药业股份有限公司 |
用于治疗性化合物的靶向配体
|
|
CN114736256B
(zh)
|
2016-06-06 |
2025-09-02 |
箭头药业股份有限公司 |
5’-环膦酸酯修饰核苷酸
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
CN109462981B
(zh)
|
2016-09-02 |
2023-07-07 |
箭头药业股份有限公司 |
靶向配体
|
|
CN109661233A
(zh)
|
2016-10-06 |
2019-04-19 |
Ionis 制药公司 |
缀合低聚化合物的方法
|
|
KR20240096846A
(ko)
|
2017-01-10 |
2024-06-26 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법
|
|
WO2018140920A1
(en)
|
2017-01-30 |
2018-08-02 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor xii gene expression
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
CR20190572A
(es)
|
2017-07-06 |
2020-05-23 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
KR102737464B1
(ko)
|
2017-09-14 |
2024-12-02 |
애로우헤드 파마슈티컬스 인코포레이티드 |
안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법
|
|
CN111212909A
(zh)
|
2017-10-17 |
2020-05-29 |
箭头药业股份有限公司 |
用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
US20210355497A1
(en)
|
2018-05-09 |
2021-11-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fxi expression
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
UA128236C2
(uk)
|
2018-12-21 |
2024-05-15 |
Айоніс Фармасутікалз, Інк. |
Модулятори експресії hsd17b13
|
|
JP2022518384A
(ja)
|
2019-01-09 |
2022-03-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
HIF-2アルファ(EPAS1)の発現を阻害するためのRNAi剤、その組成物及び使用方法
|
|
AU2020219355A1
(en)
|
2019-02-07 |
2021-09-30 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for Hepatitis B virus infection
|
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
WO2020255007A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
|
AR121446A1
(es)
|
2020-02-28 |
2022-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
US12054718B2
(en)
|
2020-03-26 |
2024-08-06 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
|
|
EP4138858A4
(en)
|
2020-04-21 |
2024-07-03 |
Flagship Pioneering, Inc. |
BIFUNCTIONAL MOLECULES AND METHODS OF USE THEREOF
|
|
IL301186A
(en)
|
2020-09-11 |
2023-05-01 |
Arrowhead Pharmaceuticals Inc |
Skeletal muscle delivery platforms and methods of use
|
|
WO2022056266A2
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
UY39420A
(es)
|
2020-09-11 |
2022-03-31 |
Arrowhead Pharmaceuticals Inc |
Conjugados lipídicos para el transporte de agentes terapéuticos
|
|
TW202227101A
(zh)
|
2020-11-18 |
2022-07-16 |
美商Ionis製藥公司 |
用於調節血管收縮素原表現之化合物及方法
|
|
AU2022254705A1
(en)
|
2021-04-08 |
2023-10-05 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
|
|
EP4326334A1
(en)
|
2021-04-23 |
2024-02-28 |
GanNA Bio, Inc. |
Glycan modified nucleic acids, methods of preparation, and therapeutic uses
|
|
KR20240014067A
(ko)
|
2021-05-28 |
2024-01-31 |
애로우헤드 파마슈티컬스 인코포레이티드 |
뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
CA3233755A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
CN119730859A
(zh)
|
2022-06-15 |
2025-03-28 |
箭头药业股份有限公司 |
用于抑制超氧化物歧化酶1(SOD1)表达的RNAi剂、其组合物及使用方法
|
|
US12378558B2
(en)
|
2023-03-21 |
2025-08-05 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use
|
|
TW202448484A
(zh)
|
2023-04-20 |
2024-12-16 |
美商雅迪克斯製藥公司 |
Mapt調節組合物及其使用方法
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
WO2024249328A2
(en)
|
2023-05-26 |
2024-12-05 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
TW202506137A
(zh)
|
2023-06-20 |
2025-02-16 |
美商雅迪克斯製藥公司 |
Lrrk2調節組合物及其使用方法
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
TW202530408A
(zh)
|
2023-09-29 |
2025-08-01 |
美商英西特羅公司 |
用於治療非酒精性脂肪肝病的組合物與方法
|
|
WO2025137384A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Methods and reagents for improved oligonucleotide synthesis
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|